Revolution Medicines to Participate in the 43rd Annual Goldman Sachs Global Healthcare Conference
09 juin 2022 16h02 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., June 09, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Revolution Medicines Reports First Quarter 2022 Financial Results and Update on Corporate Progress
09 mai 2022 16h02 HE
|
Revolution Medicines, Inc.
Lead RAS(ON) Inhibitor drug candidates RMC-6236 (RASMULTI) and RMC-6291 (KRASG12C) approaching the clinic RMC-4630-03 Phase 2 trial evaluating RAS Companion Inhibitor RMC-4630 (SHP2) in combination...
Outlook on the KRAS Inhibitors Global Market to 2028 - Key Drivers and Challenges
27 avr. 2022 05h28 HE
|
Research and Markets
Dublin, April 27, 2022 (GLOBE NEWSWIRE) -- The "Global KRAS Inhibitors Market & Clinical Trials Forecast 2028" report has been added to ResearchAndMarkets.com's offering. The advancement in...
Revolution Medicines to Report Financial Results for First Quarter 2022 After Market Close on May 9, 2022
21 avr. 2022 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...
Revolution Medicines Announces Seven Oral Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2022
09 mars 2022 07h30 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Revolution Medicines to Participate in Cowen 42nd Annual Health Care Conference
01 mars 2022 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...
Revolution Medicines Reports Fourth Quarter and Year-End 2021 Financial Results and Update on Corporate Progress
28 févr. 2022 16h05 HE
|
Revolution Medicines, Inc.
RAS(ON) Inhibitor Pipeline Continues to Advance and Expand, Now Addressing Majority of RAS-Addicted Cancers; Two New Drug Candidates Recently Nominated Recently Announced First Patient Dosed in...
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2021 After Market Close on February 28, 2022
22 févr. 2022 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...
Revolution Medicines to Provide R&D Update, Including Expansion of Development-Stage RAS(ON) Inhibitor Pipeline, During Presentation at 40th Annual J.P. Morgan Healthcare Conference
04 janv. 2022 07h30 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies for RAS-addicted...
Revolution Medicines to Participate in 4th Annual Evercore ISI HealthCONx Conference
24 nov. 2021 07h30 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit...